NEW YORK (GenomeWeb News) — Proteome Sciences' CEO Christopher Pearce has increased an existing loan facility to the company from £4 million ($8 million) to £6 million, the company said today.
 
Proteome said the additional cash will keep the company solvent until it starts recording revenue from its ProteoShop biomarker portfolio.
 
The expanded facility will also enable the firm to out-license its TMT products, which it expects to happen sometime during the next five months.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Women with breast or ovarian cancer living in medically underserved regions of the US are less likely to get recommended BRCA1 or BRCA2 genetic testing, according to a new study.

Three immunology researchers are to receive this year's Albany Medical Center Prize in Medicine and Biomedical Research, the Albany Times-Union reports.

In Genome Research this week: clonal evolution analysis of acute myeloid leukemia, computational pipeline to examine relationships between bacterial pathogens, and more.

Elephants may have "re-animated" a pseudogene to help stave off cancer, according to the New York Times.